Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943.
   PubMed Web of Science ®Google Scholar
• Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with Hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–853.
   PubMed Web of Science ®Google Scholar
• Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol. 2019;12(1):133.
   PubMed Web of Science ®Google Scholar
• Chen F. Molecular signature of hepatocellular carcinoma, hope or hype in prognosis and therapy. Semin Cancer Biol. 2011;21(1):1–3.
   PubMed Web of Science ®Google Scholar
• Dawkins J, Webster RM. The hepatocellular carcinoma market, Nature reviews. Drug Discovery. 2019;18(1):13–14.
   Google Scholar
• Breuhahn K, Gores G, Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology. 2011;53(6):2112–2121.
   PubMed Web of Science ®Google Scholar
• Milane L, Singh A, Mattheolabakis G, Suresh M, Amiji MM. Exosome mediated communication within the tumor microenvironment. J Control Release. 2015;219:278–294.
   PubMed Web of Science ®Google Scholar
• Morishita M, Takahashi Y, Nishikawa M, Takakura Y. Pharmacokinetics of exosomes-an important factor for elucidating the biological roles of exosomes and for the development of exosome-based therapeutics. J Pharm Sci. 2017;106(9):2265–2269.
   PubMed Web of Science ®Google Scholar
• De Toro J, Herschlik L, Waldner C, Mongini C. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol. 2015;6:203.
   PubMed Web of Science ®Google Scholar
• Tkach M, Théry C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016;164(6):1226–1232.
   PubMed Web of Science ®Google Scholar
• Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30(6):836–848.
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhou L, Lv D, Zhu X, Tang H. Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. J Hematol Oncol. 2019;12(1):53.
   PubMedGoogle Scholar
• Wang F, Li L, Piontek K, Sakaguchi M, Selaru FM. Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma. Hepatology (Baltimore, Md). 2018;67(3):940–954.
   PubMed Web of Science ®Google Scholar
• Li R, Wang Y, Zhang X, et al. Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. Mol Cancer. 2019;18(1):18.
   PubMed Web of Science ®Google Scholar
• Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets. Semin Liver Dis. 2019;39(1):26–42.
   PubMed Web of Science ®Google Scholar
• Tang B, Zhu J, Li J, et al. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma. Cell Commun Signaling. 2020;18(1):174.
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232.
   PubMed Web of Science ®Google Scholar
• Zhang HH, Mei MH, Fei R, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat. 2010;17(Suppl 1):34–43.
   PubMedGoogle Scholar
• Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z. PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol. 2008;45(4):963–970.
   PubMed Web of Science ®Google Scholar
• Nakamoto N, Cho H, Shaked A, et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 2009;5(2):e1000313.
   PubMed Web of Science ®Google Scholar
• Ye L, Zhang Q, Cheng Y, et al. Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J Immunother Cancer. 2018;6(1):145.
   PubMedGoogle Scholar
• Han Q, Zhao H, Jiang Y, Yin C, Zhang J. HCC-derived exosomes: critical player and target for cancer immune escape. Cells. 2019;8:6.
   Web of Science ®Google Scholar
• Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol. 2016;65(5):1031–1042.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9:559.
   PubMed Web of Science ®Google Scholar
• Van Calster B, Wynants L, Verbeek JFM, et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur Urol. 2018;74(6):796–804.
   PubMed Web of Science ®Google Scholar
• Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2018;5(12):181006.
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945.
   PubMed Web of Science ®Google Scholar
• Zheng Z, Liang W, Wang D, et al. Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis. Int J Cancer. 2015;136(6):E751–9.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen H, Zhang J, et al. MCM family in gastrointestinal cancer and other malignancies: from functional characterization to clinical implication. Biochimica Et Biophysica Acta. 2020;1874(2):188415.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Huang J, Zhang C, et al. The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex formation and regulates homologous recombination-mediated repair. Nat Commun. 2020;11(1):2639.
   PubMed Web of Science ®Google Scholar
• Higuchi F, Nagashima H, Ning J, Koerner MVA, Wakimoto H, Cahill DP. Restoration of temozolomide sensitivity by PARP inhibitors in mismatch repair deficient glioblastoma is independent of base excision repair. Clin Cancer Res. 2020;26(7):1690–1699.
   PubMed Web of Science ®Google Scholar
• Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110.
   PubMed Web of Science ®Google Scholar
• Dong P, Xiong Y, Yue J, Hanley SJB, Watari H. B7H3 as a promoter of metastasis and promising therapeutic target. Front Oncol. 2018;8:264.
   PubMed Web of Science ®Google Scholar
• Parisi G. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy?. Eur J Intern Med. 2012;23(1):34–36.
   PubMed Web of Science ®Google Scholar
• Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5(3):215–219.
   PubMed Web of Science ®Google Scholar
• Li X, Xu W, Kang W, et al. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features. Theranostics. 2018;8(6):1740–1751.
   PubMed Web of Science ®Google Scholar
• Liu PH, Hsu CY, Hsia CY, et al. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J Hepatol. 2016;64(3):601–608.
   PubMed Web of Science ®Google Scholar
• Yan X, Qiu Y. Impact of current staging systems on treatment strategy for HBV-related hepatocellular carcinoma. Cancer Lett. 2016;379(2):220–224.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Singal AG. Surveillance for Hepatocellular carcinoma: current best practice and future direction. Gastroenterology. 2019;157(1):54–64.
   PubMed Web of Science ®Google Scholar
• Sasaki R, Kanda T, Yokosuka O, Kato N, Matsuoka S, Moriyama M. Exosomes and Hepatocellular carcinoma: from bench to bedside. Int J Mol Sci. 2019;20:6.
   Google Scholar
• Liu H, Li B. The functional role of exosome in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2018;144(11):2085–2095.
   PubMed Web of Science ®Google Scholar
• Maliga Z, Junqueira M, Toyoda Y, et al. A genomic toolkit to investigate kinesin and myosin motor function in cells. Nat Cell Biol. 2013;15(3):325–334.
   PubMed Web of Science ®Google Scholar
• Hartman MA, Finan D, Sivaramakrishnan S, Spudich JA. Principles of unconventional myosin function and targeting. Annu Rev Cell Dev Biol. 2011;27:133–155.
   PubMed Web of Science ®Google Scholar
• Xie X, Wang X, Liao W, et al. MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development. J Exp Clin Cancer Res. 2018;37(1):28.
   PubMedGoogle Scholar
• Kumar R, Gardner A, Homan CC, et al. Severe neurocognitive and growth disorders due to variation in THOC2, an essential component of nuclear mRNA export machinery. Hum Mutat. 2018;39(8):1126–1138.
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu X, Zhang G, et al. Knockdown THOC2 suppresses the proliferation and invasion of melanoma. Bioengineered. 2019;10(1):635–645.
   PubMed Web of Science ®Google Scholar
• Seo N, Akiyoshi K, Shiku H. Exosome-mediated regulation of tumor immunology. Cancer Sci. 2018;109(10):2998–3004.
   PubMed Web of Science ®Google Scholar
• Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120(2):457–471.
   PubMed Web of Science ®Google Scholar
• Ruivo CF, Adem B, Silva M, Melo SA. The biology of cancer exosomes: insights and new perspectives. Cancer Res. 2017;77(23):6480–6488.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Invest. 2016;126(4):1216–1223.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287.
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Nakamoto Y, Arai K, et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology (Baltimore, Md). 2011;53(4):1206–1216.
   PubMed Web of Science ®Google Scholar
• Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 2018;48(2):103–114.
   PubMed Web of Science ®Google Scholar
• Berti M, Teloni F, Mijic S, et al. Sequential role of RAD51 paralog complexes in replication fork remodeling and restart. Nat Commun. 2020;11(1):3531.
   PubMed Web of Science ®Google Scholar
• Natsume A, Hirano M, Ranjit M, Aoki K, Wakabayashi T. Aberrant transcriptional regulation of super-enhancers by RET finger protein-histone deacetylase 1 complex in glioblastoma: chemoresistance to temozolomide. Neurol Med Chir (Tokyo). 2019;59(8):293–298.
   PubMed Web of Science ®Google Scholar